Cost comparisons between nafarelin and leuprolide in the treatment of endometriosis
article
OA: closed
CC0
⤵ 3 in-corpus citations
AI-generated summary
This study compared the costs of nafarelin and leuprolide treatments for endometriosis.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
The objective of this study was to compare the cost and effectiveness of nafarelin versus leuprolide in the treatment of endometriosis. To compare the economic impact of treating endometriosis with leuprolide or nafarelin and to facilitate cost comparisons between the two, we statistically analyzed information concerning the costs of medications for the treatment of endometriosis, outpatient services, and management of adverse effects, as well as other related costs. A national claims database, MarketScan, was used to obtain data on patients with a principal diagnosis of endometriosis who were treated with either leuprolide or nafarelin. During the calendar years 1992-1994, 114 patients with endometriosis had claims for nafarelin, and 343 had claims for leuprolide. There were no significant differences between nafarelin and leuprolide recipients with respect to demographic variables, types of concomitant drug used, types of outpatient service received, or major outpatient diagnostic categorization. In 1994 dollars, the cost of using leuprolide was $326.7 greater than that of using nafarelin. The results of this study suggest that nafarelin is a less expensive alternative to leuprolide for the treatment of endometriosis.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (22)
- 9 Endometriosis: Medical therapy via openalex
- Administration of Nasal Nafarelin as Compared with Oral Danazol for Endometriosis via openalex
- Endometriosis 1990 via openalex
- Epidemiology of Endometriosis via openalex
- EPIDEMIOLOGY OF ENDOMETRIOSIS via openalex
- Intranasal treatment with luteinising hormone releasing hormone agonist in women with endometriosis. via openalex
- Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study via openalex
- “MEDICAL OOPHORECTOMY” USING A LONG-ACTING GNRH AGONIST-A POSSIBLE NEW APPROACH TO THE TREATMENT OF ENDOMETRIOSIS. via openalex
- Nafarelin for endometriosis: a large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up via openalex
- Nafarelin for endometriosis: A large-scale, danazol-controlled trial of efficacy and safety, with 1-year follow-up via openalex
- Nafarelin vs. leuprolide acetate depot for endometriosis. Changes in bone mineral density and vasomotor symptoms. Nafarelin Study Group. via openalex
- Prospective randomized double-blind trial of 3 versus 6 months of nafarelin therapy for endometriosis associated pelvic pain via openalex
- Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist. via openalex
- W2405461450 via openalex
- W2412636952 via openalex
- W2088438184 via openalex
- W2465357600 via openalex
- W1967894943 via openalex
- W3022929224 via openalex
- W1566936261 via openalex
- W6641127482 via openalex
- W6777152678 via openalex
Cited by (3)
Source provenance
- europepmc
- last seen: 2026-07-27T06:15:28.040536+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:10:40.754221+00:00
License: CC0
· commercial use OK